Safety, Tolerability, Pharmacokinetics (PK) & Pharmacodynamics (PD) of

See also
Status	Clinical Trial	Phase
Completed	`NCT03674125` - Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection	Phase 1
Completed	`NCT00978497` - Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection	Phase 2
Completed	`NCT00170131` - MMF Influence on HCV Viral Evolution After Liver Transplantation	Phase 4
Completed	`NCT04008927` - A Community-based Intervention Among Active Drug Users in Montpellier	N/A
Active, not recruiting	`NCT04044586` - HIV and HCV Infections in 2 Communes From the Battambang Province, Cambodia: Prevalence Rates, Viral Strains, and Unsafe Injection Practices (12352 ANRS ROK INVEST)
Completed	`NCT01958281` - Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency	Phase 2
Completed	`NCT02533427` - Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol	Phase 1
Completed	`NCT02783976` - Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice
Withdrawn	`NCT04309734` - Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects	Phase 1/Phase 2
Completed	`NCT01965535` - Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection	Phase 2
Completed	`NCT00743795` - Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection	Phase 2
Completed	`NCT00768690` - A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333	Phase 1
Withdrawn	`NCT04235049` - Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE)	Phase 4
Terminated	`NCT00401947` - A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection	Phase 2
Completed	`NCT00959699` - A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)	Phase 2
Completed	`NCT00623649` - Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection	Phase 1
Completed	`NCT00221624` - Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients	Phase 3
Completed	`NCT04134767` - Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)	N/A
Completed	`NCT02402452` - Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment	Phase 1
Completed	`NCT00909311` - Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir	Phase 1

NCT number	NCT03588923
Study type	Interventional
Source	Nanjing Sanhome Pharmaceutical, Co., Ltd.
Contact
Status	Completed
Phase	Phase 1
Start date	July 7, 2018
Completion date	August 10, 2018

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms